Pharmaceutical formulations
AssigneeNovo Nordisk A/S
InventorsTommy Sander, Christian Poulsen, Rosa Rebecca Erritzoee Hansen
Life of this patent
Estimating the term…
Abstract
Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein.
Claims25
A method of treating obesity or overweight in a subject in need thereof, comprising administering a fixed-dose combination of 0.025-5.0 mg cagrilintide and 0.05-5.0 mg semaglutide subcutaneously in a single injection.
A method of treating obesity or overweight in a subject in need thereof, comprising administering subcutaneously in a single injection
- 0.25 mg cagrilintide and 0.25 mg semaglutide once a week for four weeks (weeks 0-3);
- 0.5 mg cagrilintide and 0.5 semaglutide once a week for four weeks (weeks 4-7);
- 1.0 mg cagrilintide and 1.0 semaglutide once a week for four weeks (weeks 8-11);
- 1.7 mg cagrilintide and 1.7 mg semaglutide once a week for four weeks (weeks 12-15);
- and
- 2.4 mg cagrilintide and 2.4 mg semaglutide mg once a week thereafter.
A method of treating diabetes or delaying diabetes progression, or delaying or reducing the development of a major adverse cardiovascular event (MACE), or treating non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) in a subject in need thereof, comprising administering a fixed-dose combination of 0.025-5.0 mg cagrilintide and 0.05-5.0 mg semaglutide subcutaneously in a single injection.
Dependencies are inferred from the claim text.